UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 20, 2018
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
Commission FileNumber: 001-34207
| Delaware | 33-0728374 | |
(State or other jurisdiction of incorporation) | (IRS Employer Identification No.) |
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510)848-5100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. | Other Events |
On October 20, 2018, Dynavax Technologies Corporation (“Dynavax”), issued a press release and presented a corresponding poster announcing data from its ongoing Phase 1b/2SYNERGY-001 study investigatingSD-101, Dynavax’s intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), ananti-PD-1 therapy developed by Merck & Co., Inc. (known as MSD outside the United States and Canada) in patients with advanced melanoma naïve toanti-PD-1/L1 therapy, at the 2018 European Society for Medical Oncology Congress, in Munich, Germany (“ESMO”). Dynavax presented two additional posters at ESMO, one was presented October 20, 2018, and the other October 21, 2018. On October 21, 2018, Dynavax held a conference call and webcast to review all data the company presented at ESMO. A copy of the press release, posters and the conference call presentation are filed as Exhibits 99.1, 99.2 and 99.3 to this Current Report on Form8-K and are incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dynavax Technologies Corporation | ||||||
| Date: October 22, 2018 | By: | /s/ DAVID JOHNSON | ||||
| David Johnson | ||||||
| Vice President | ||||||